CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Liminatus Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Liminatus Pharma Inc
6 Centerpointe Dr., #625
Phone: (213) 273-5453p:213 273-5453 LA PALMA, CA  90623  United States Ticker: LIMNLIMN
Business Summary
Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
6770 Blank checks

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director ChrisKim 65 4/30/2025 4/30/2025
Chief Financial Officer ScottDam 46 4/30/2025 4/30/2025
Chief Technology Officer Beom K.Choi 53 4/30/2025 4/30/2025
7 additional Officers and Directors records available in full report.

Business Names
Business Name
ATVC
ATVCU
IRAA
Liminatus Pharma, Inc.
LIMN
LIMNW

General Information
Outstanding Shares: 26,014,633 (As of 4/30/2025)
Shareholders: 6
Stock Exchange: NASD
Federal Tax Id: 853901431
Fax Number: (302) 636-5454


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, May 30, 2025